This Under-the-Radar Drug Developer May Have an Answer for Patients With Severe COVID-19
Vanda Pharmaceuticals (NASDAQ: VNDA) may not be a household name, but it could boost your net worth. The specialty pharma's two marketed drugs generated sales totaling $227.2 million in 2019 and $58 million in the first quarter of 2020, a 22% increase over the prior year.
Its strategy is to expand the approved indications for those drugs and complete development of drug candidates tradipitant and VTR-297. Vanda just launched a phase 3 clinical trial with tradipitant to treat patients with COVID-19 acute respiratory distress syndrome.
Image source: Getty Images.
Source Fool.com
